331 related articles for article (PubMed ID: 32929365)
41. Study of the role played by NfsA, NfsB nitroreductase and NemA flavin reductase from Escherichia coli in the conversion of ethyl 2-(2'-nitrophenoxy)acetate to 4-hydroxy-(2H)-1,4-benzoxazin-3(4H)-one (D-DIBOA), a benzohydroxamic acid with interesting biological properties.
Valle A; Le Borgne S; Bolívar J; Cabrera G; Cantero D
Appl Microbiol Biotechnol; 2012 Apr; 94(1):163-71. PubMed ID: 22173483
[TBL] [Abstract][Full Text] [Related]
42. Radiation dosimetry and biodistribution of the hypoxia tracer (18)F-EF5 in oncologic patients.
Lin LL; Silvoniemi A; Stubbs JB; Rengan R; Suilamo S; Solin O; Divgi C; Eskola O; Sorger JM; Stabin MG; Kachur A; Hahn SM; Grönroos TJ; Forsback S; Evans SM; Koch CJ; Minn H
Cancer Biother Radiopharm; 2012 Sep; 27(7):412-9. PubMed ID: 22897720
[TBL] [Abstract][Full Text] [Related]
43. Biodistribution of the nitroimidazole EF5 (2-[2-nitro-1H-imidazol-1-yl]-N-(2,2,3,3,3-pentafluoropropyl) acetamide) in mice bearing subcutaneous EMT6 tumors.
Laughlin KM; Evans SM; Jenkins WT; Tracy M; Chan CY; Lord EM; Koch CJ
J Pharmacol Exp Ther; 1996 May; 277(2):1049-57. PubMed ID: 8627516
[TBL] [Abstract][Full Text] [Related]
44. Detection of hypoxic cells with the 2-nitroimidazole, EF5, correlates with early redox changes in rat brain after perinatal hypoxia-ischemia.
Bergeron M; Evans SM; Sharp FR; Koch CJ; Lord EM; Ferriero DM
Neuroscience; 1999; 89(4):1357-66. PubMed ID: 10362320
[TBL] [Abstract][Full Text] [Related]
45. Noninvasive molecular imaging of hypoxia in human xenografts: comparing hypoxia-induced gene expression with endogenous and exogenous hypoxia markers.
He F; Deng X; Wen B; Liu Y; Sun X; Xing L; Minami A; Huang Y; Chen Q; Zanzonico PB; Ling CC; Li GC
Cancer Res; 2008 Oct; 68(20):8597-606. PubMed ID: 18922936
[TBL] [Abstract][Full Text] [Related]
46. Hypoxia-inducible regulation of a prodrug-activating enzyme for tumor-specific gene therapy.
Shibata T; Giaccia AJ; Brown JM
Neoplasia; 2002; 4(1):40-8. PubMed ID: 11922390
[TBL] [Abstract][Full Text] [Related]
47. Biochemical characterization of NfsA, the Escherichia coli major nitroreductase exhibiting a high amino acid sequence homology to Frp, a Vibrio harveyi flavin oxidoreductase.
Zenno S; Koike H; Kumar AN; Jayaraman R; Tanokura M; Saigo K
J Bacteriol; 1996 Aug; 178(15):4508-14. PubMed ID: 8755878
[TBL] [Abstract][Full Text] [Related]
48. The 3D-structure, kinetics and dynamics of the E. coli nitroreductase NfsA with NADP
White SA; Christofferson AJ; Grainger AI; Day MA; Jarrom D; Graziano AE; Searle PF; Hyde EI
FEBS Lett; 2022 Sep; 596(18):2425-2440. PubMed ID: 35648111
[TBL] [Abstract][Full Text] [Related]
49. Imaging of Tumor Hypoxia With 18F-EF5 PET/MRI in Cervical Cancer.
Narva SI; Seppänen MP; Raiko JRH; Forsback SJ; Orte KJ; Virtanen JM; Hynninen J; Hietanen S
Clin Nucl Med; 2021 Dec; 46(12):952-957. PubMed ID: 34619699
[TBL] [Abstract][Full Text] [Related]
50. Noninvasive optical imaging of nitroreductase gene-directed enzyme prodrug therapy system in living animals.
Bhaumik S; Sekar TV; Depuy J; Klimash J; Paulmurugan R
Gene Ther; 2012 Mar; 19(3):295-302. PubMed ID: 21753794
[TBL] [Abstract][Full Text] [Related]
51. Advances in imaging gene-directed enzyme prodrug therapy.
Bhaumik S
Curr Pharm Biotechnol; 2011 Apr; 12(4):497-507. PubMed ID: 21342105
[TBL] [Abstract][Full Text] [Related]
52. Regulation of the nfsA Gene in Escherichia coli by SoxS.
Paterson ES; Boucher SE; Lambert IB
J Bacteriol; 2002 Jan; 184(1):51-8. PubMed ID: 11741843
[TBL] [Abstract][Full Text] [Related]
53. Mechanism of chromate reduction by the Escherichia coli protein, NfsA, and the role of different chromate reductases in minimizing oxidative stress during chromate reduction.
Ackerley DF; Gonzalez CF; Keyhan M; Blake R; Matin A
Environ Microbiol; 2004 Aug; 6(8):851-60. PubMed ID: 15250887
[TBL] [Abstract][Full Text] [Related]
54. Anaerobic bacteria as a gene delivery system that is controlled by the tumor microenvironment.
Lemmon MJ; van Zijl P; Fox ME; Mauchline ML; Giaccia AJ; Minton NP; Brown JM
Gene Ther; 1997 Aug; 4(8):791-6. PubMed ID: 9338007
[TBL] [Abstract][Full Text] [Related]
55. A simplified synthesis of the hypoxia imaging agent 2-(2-Nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-[(18)F]pentafluoropropyl)-acetamide ([18F]EF5).
Chitneni SK; Bida GT; Dewhirst MW; Zalutsky MR
Nucl Med Biol; 2012 Oct; 39(7):1012-8. PubMed ID: 22727821
[TBL] [Abstract][Full Text] [Related]
56. MicroPET imaging of bacterial infection with nitroreductase-specific responsive
Huang L; Fang J; Hong S; Liu H; Zhu H; Feng L; Zhuang R; Zhao X; Guo Z; Zhang X
Eur J Nucl Med Mol Imaging; 2022 Jul; 49(8):2645-2654. PubMed ID: 35122512
[TBL] [Abstract][Full Text] [Related]
57. 18F-EF5 PET Is Predictive of Response to Fractionated Radiotherapy in Preclinical Tumor Models.
Ali R; Apte S; Vilalta M; Subbarayan M; Miao Z; Chin FT; Graves EE
PLoS One; 2015; 10(10):e0139425. PubMed ID: 26431331
[TBL] [Abstract][Full Text] [Related]
58. Detection of individual hypoxic cells in multicellular spheroids by flow cytometry using the 2-nitroimidazole, EF5, and monoclonal antibodies.
Woods ML; Koch CJ; Lord EM
Int J Radiat Oncol Biol Phys; 1996 Jan; 34(1):93-101. PubMed ID: 12118570
[TBL] [Abstract][Full Text] [Related]
59. Pharmacokinetics of EF5 [2-(2-nitro-1-H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl) acetamide] in human patients: implications for hypoxia measurements in vivo by 2-nitroimidazoles.
Koch CJ; Hahn SM; Rockwell K; Covey JM; McKenna WG; Evans SM
Cancer Chemother Pharmacol; 2001 Sep; 48(3):177-87. PubMed ID: 11592338
[TBL] [Abstract][Full Text] [Related]
60. Immune enhancement of nitroreductase-induced cytotoxicity: studies using a bicistronic adenovirus vector.
Green NK; McNeish IA; Doshi R; Searle PF; Kerr DJ; Young LS
Int J Cancer; 2003 Mar; 104(1):104-12. PubMed ID: 12532426
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
